INTRODUCTION
Constipation is a common, oft en chronic, gastrointestinal problem that has a signifi cant negative impact on health-related quality of life ( 1, 2 ) . Chronic constipation is diagnosed using the Rome III criteria ( 3 ) or, more commonly in clinical practice, by the patient ' s symptoms of infrequent, diffi cult, or unsatisfactory bowel evacuation.
Prevalence estimates for chronic constipation vary more according to defi nition than to geography, but are generally between 10 and 15 % for developed countries ( 4, 5 ) . It is thought that the majority of patients with constipation experience slow-transit constipation, in which the rate of colonic transit is reduced ( 6 ) ; however, a relationship between symptoms of constipation (stool consistency and frequency of bowel movements) and colonic transit time (CTT) has never been convincingly demonstrated.
Prucalopride is a selective, high-affi nity, 5-hydroxytryptamine receptor-4 agonist with gastrointestinal prokinetic properties. Th e high affi nity and selectivity for 5-hydroxytryptamine receptor-4 diff erentiates prucalopride from older generation compounds, such as cisapride and tegaserod, and minimizes the potential for target-unrelated side eff ects ( 7, 8 ) . Phase 3 clinical trials have shown prucalopride to be eff ective in improving stool frequency ( 9 -11 ) and it is also eff ective in reducing abdominal and stool-related symptoms associated with constipation ( 12 Constipation is often characterized by slow colonic transit, but the relationship between colonic transit time (CTT) and symptoms is unclear. The aims of this study were to investigate the effect of prucalopride, a 5-hydroxytryptamine receptor-4 agonist, on CTT and assess the relationship between CTT and symptoms.
METHODS:
This was an integrated analysis of three randomized, placebo-controlled, phase 2 dose-fi nding trials of prucalopride in patients with chronic constipation (ClinicalTrials.gov identifi ers: NCT00617513; NCT00631813; and NCT00596596). Measurements of CTT were analyzed using radio-opaque markers at the start and end (4 or 12 weeks) of treatment. At these visits, patients assessed the presence and severity of their symptoms.
RESULTS:
In total, 280 patients had CTT measurements before and at the end of treatment and were included in the analysis. 
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symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Th e recommended dose is 2 mg once daily for adults or 1 mg once daily for patients who are over 65 years old. A consistent eff ect of prucalopride on CTT has not yet been reported in patients with chronic constipation. Some phase 2 trials have shown that prucalopride treatment results in decreased orocecal transit time ( 13 ) and reduced CTT ( 14, 15 ) , but other phase 2 trials have reported a less conclusive eff ect of prucalopride on CTT ( 16, 17 ) .
Th e aims of this study were twofold: fi rst, to evaluate the eff ects of prucalopride on CTT in a large population, and, second, to assess the relationship between CTT and symptoms of constipation. To address these aims, an integrated analysis was performed that combined CTT data obtained from three placebo-controlled phase 2 trials before and aft er prucalopride treatment.
METHODS

Population
Th e present study is an integrated analysis of patient data from three randomized, placebo-controlled, phase 2 dose-fi nding trials in patients with chronic constipation (INT-1, INT-2, and USA-3; ClinicalTrials. gov identifi ers: NCT00617513; NCT00631813; and NCT00596596) ( 14, 18, 19 ). An integrated analysis approach was used to provide as much data as possible for addressing the study aims.
Design of the phase 2 trials
Th e main inclusion criterion for these trials was chronic constipation, defi ned as two or fewer spontaneous complete bowel movements (SCBMs) per week in combination with straining, sensation of incomplete evacuation, or hard stools for ≥ 25 % of stools. Secondary constipation was the main exclusion criterion.
For each trial, there was a run-in period of 4 weeks. Patients were then treated with either placebo or prucalopride once daily for 4 weeks (INT-1 and USA-3) or for 12 weeks (INT-2). Key trial objectives were to assess CTT; the number of SCBMs per week; stool consistency (measured on a 5-point scale from − 2 (watery) to + 2 (very hard)); and symptom severity. CTT was measured at baseline (before the fi rst dose of investigational product) and at the end of treatment. All patients maintained a daily bowel symptom diary, and subjective assessments by the patient of symptom severity and stool consistency were made at every fortnightly visit.
Laxatives were not permitted during the trials, except for the use of bisacodyl as a rescue medication if the patient had not passed stool for at least 3 consecutive days. Th e use of laxative rescue medication was not permitted during the CTT measurements (baseline and end of treatment).
Transit time measurements and analysis
CTT was measured using a slightly modifi ed version of the Metcalf method ( 20, 21 ) . A capsule containing 10 radio-opaque markers was given to the patient every day for 6 consecutive days (INT-1 and INT-2) or a capsule of 24 markers was taken on each of 3 consecutive days (USA-3), with each capsule containing markers of a diff erent shape. Th e exact times at which the doses were taken were recorded in the daily bowel symptom diaries. A single abdominal X-ray taken on the day aft er the administration of fi nal dose of markers (immediately before the start of treatment or at the end of treatment) was used to calculate CTT based on the number of markers present, according to the Metcalf method ( 20, 21 ) .
Integrated study design
Th e present study includes participants from these phase 2 trials who were treated with a placebo or prucalopride 2 or 4 mg and for whom there were valid measurements of CTT before and at the end of treatment. Post-treatment CTT measurements were combined irrespective of treatment duration. Th is was not expected to aff ect the results, as other clinical effi cacy outcomes were similar at week 4 and at the end of the 12-week trial.
Patients with a CTT of 48 h or less were defi ned as having normal colonic transit, patients with a CTT of more than 48 h were defi ned as having slow colonic transit, and patients with a CTT of more than 96 h were defi ned as having very slow colonic transit. Th ese thresholds were set on the basis of clinical experience and evidence from previous trials, which have shown mean normal CTTs in adults without constipation to be less than 48 h, and upper normal limits for CTTs to be less than 96 h ( 21 -23 ). Individual symptoms and stool consistency were analyzed using the results of questionnaires taken at the same time that CTT measurements were carried out, before and at the end of treatment. Symptom defi nitions were pooled for this analysis, as shown in Table 1 , because symptom defi nitions diff ered slightly among trials.
Statistical analyses
Response to treatment was defi ned in the same way as in the phase 3 pivotal trials of prucalopride ( 9 -11 ): patients were defi ned as responders when they had a mean of three or more SCBMs per week over the whole double-blind treatment period. Descriptive statistics for CTT before and at the end of treatment, and the change from baseline in CTT, were calculated for all patients, for those with slow or very slow CTT and normal CTT at baseline, and for responders and nonresponders in each treatment group. Signifi cance of the change from before treatment to the end of treatment in each group was evaluated by a paired t -test. Th e comparisons between treatment groups and the placebo group were evaluated with the two-sample t -test.
Symptom scores were linked with CTT values that were assessed at the same time. Stool consistency was analyzed using data recorded at the same time as that at which the CTT measurements were carried out. Statistical comparisons were carried out using a Cochran -Mantel -Haenszel test, assessing a nonzero correlation. Statistical analyses were performed using Statistical Analysis System (SAS) soft ware, version 9.2 (SAS Institute, Cary, NC).
FUNCTIONAL GI DISORDERS
Prucalopride Improves Bowel Function and CTT
RESULTS
Patient population and characteristics
From the 651 patients who completed the three phase 2 trials, 280 (43 % ) were eligible for inclusion in this study because they had a CTT measurement taken both before and at the end of treatment with placebo, prucalopride 2 mg, or prucalopride 4 mg ( Table 2 ) .
Of the 280 patients included in the integrated analysis, 112 were treated with placebo, 98 with prucalopride 2 mg, and 70 with prucalopride 4 mg ( Table 2 ). Th eir mean age was 43 years (range: 18 -70 years), and they had a mean duration of constipation of 19 years (range: 0.5 -64 years). Most patients (93 % ) in this study were women. Th ese baseline characteristics were comparable across the three treatment groups, and were similar to the overall population enrolled in the three phase 2 trials, in which there was a mean age of 42 years, a mean duration of constipation of 18.3 years, and a preponderance of women (92 % ).
CTT measurements
Mean baseline CTT across all groups was ~ 66 h ( Table 2 ) . Overall, 70 % of patients had a slow or very slow CTT at baseline (i.e., > 48 h) and 30 % had a normal CTT. Th e proportions of patients with slow or very slow CTTs at baseline were similar across the three treatment groups. Compared with CTT measurements before treatment and an increase in CTT of 0.5 h (95 % confi dence interval (CI): -4.5, 5.5, P > 0.05) at the end of treatment in the placebo group, CTTs at the end of treatment were significantly reduced in the prucalopride 2 and 4 mg groups by 12.0 h (95 % CI: − 18.9, − 5.1; P < 0.001) and 13.9 h (95 % CI: -20.5, -7.4; P < 0.001), respectively ( Figure 1a ) . Th e change in CTT was not signifi cantly diff erent between trials, as evaluated using a general linear model. Aft er treatment with placebo, a normal CTT was identifi ed in 16 % of the patients who had slow or very slow CTTs at baseline. Of the patients with slow or very slow CTTs at baseline, 36 and 38 % achieved a normal CTT aft er treatment with prucalopride 2 and 4 mg, respectively. Of patients with a normal CTT at baseline, 58 % had normal CTTs at the end of the trials in the placebo group compared with 68 % in the prucalopride 2 mg group and 65 % in 
Relationship between CTT and response to prucalopride
The proportions of patients in the present study with at least three SCBMs per week (responders) were significantly higher in both prucalopride 2 mg (42 % , 41 / 98) and prucalopride 4 mg (44 % , 31 / 70) groups than in the group receiving placebo (21 % , 23 / 112; Figure 2a ). The mean CTT across all groups at the end of the study was 43 h for responders and 61 h for nonresponders. Overall, the mean CTT at the end of treatment was significantly shorter for responders than for nonresponders in all treatment groups ( Figure 2b ). Mean CTTs were 61.3, 60.0, and 69.9 h for nonresponders and 42.0, 44.6, and 50.6 h for responders in the prucalopride 2 mg, prucalopride 4 mg, and placebo groups, respectively (all P < 0.05). Th erefore, the relationship between CTT and responder status was present irrespective of treatment group; however, CTTs were numerically shorter for patients treated with prucalopride than for those who received placebo.
Of patients with normal CTT at the end of treatment, 28 % of the placebo group was responders compared with 51 and 59 % of the prucalopride 2 mg and prucalopride 4 mg groups, respectively. Of the total patient population, the proportions of patients with normal CTT at the end of treatment were 39 % in the placebo group and 56 and 61 % in the prucalopride 2 mg and prucalopride 4 mg groups, respectively.
Relationship between CTT and symptom severity
Th e relationship between CTT and symptom severity is shown in Figure 3 . Compared with patients with normal CTTs, a higher proportion of patients with slow or very slow CTTs at the end of treatment reported the following symptoms as severe or very 
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Prucalopride Improves Bowel Function and CTT was similar across both prucalopride groups and the placebo group. Th e proportion of bowel movements with stools of normal consistency and the proportion of bowel movements with hard / very hard stools were both similar across the three groups ( Figure 4 ).
DISCUSSION
Th is study demonstrates that there is a relationship between CTT and abdominal symptom severity, stool consistency, and frequency of bowel movements. It also demonstrates that CTT can be accelerated in some patients by treatment with prucalopride 2 mg, with mean CTT reduced by 12 h from baseline aft er 4 -12 weeks of treatment. In fact, 36 % patients with slow or very slow CTT had normalized transit times following treatment with prucalopride 2 mg. Such data have not previously been reported for laxatives or other prokinetics ( 24 ) .
Th e results indicate that there is an improvement in CTT for patients treated with prucalopride (mean reductions in CTT of ~ 12 -14 h) and not for those receiving placebo (mean increase in CTT of ~ 0.5 h). Patients who responded to treatment (i.e., who achieved at least three SCBMs per week) decreased their CTTs more than nonresponders in all three treatment groups, with a mean posttreatment CTT of 43 vs. 61 h, respectively. A higher severe: abdominal bloating / fl atulence / distension ( P = 0.074), straining ( P = 0.006), incomplete evacuation ( P = 0.0664), and unproductive calls to stool ( P = 0.066). A similar relationship was also seen for abdominal pain / cramps, but was less pronounced ( P = 0.112). Interestingly, severe or very severe urgency was reported more frequently among patients with normal CTTs than in those with slow or very slow CTTs ( P = 0.014).
Correlation between CTT and stool consistency
Regression analysis indicated a correlation between stool consistency and CTT (Pearson ' s correlation coeffi cient: 0.40). A 1-point increase in stool consistency in spontaneous bowel movements (representing harder stools) correlated with an 18-h increase in CTT.
Stool consistency was evaluated for all bowel movements in the last week of treatment. Stool consistency improved following prucalopride treatment compared with placebo in patients who had normal CTTs at the end of treatment ( Figure 4 ) . Th e mean proportion of bowel movements with stools of normal consistency in this patient subgroup was ~ 20 % higher, and the mean proportion of bowel movements with hard / very hard stools was ~ 20 % lower, in patients treated with prucalopride compared with those who received placebo.
Among patients with slow or very slow CTTs at the end of the trials, the consistency of stools in the last week of treatment 
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proportion of patients treated with prucalopride were responders than those who received placebo. Th ree phase 3 pivotal trials have previously demonstrated that prucalopride is eff ective at treating constipation compared with placebo ( 9 -11 ) . Integrated analyses of these trials have confi rmed the positive impact of prucalopride on clinical end points, including stool frequency, stool consistency, and reduction in the need for rescue medication, as well as in the results of the patient assessment of constipation symptoms questionnaire ( 12, 25 ) . Th e demographics of the patients in the phase 2 trials were similar to those of patients in the phase 3 pivotal trials of prucalopride ( 9 -11 ) . In the phase 3 trials, there was a higher proportion of responders among patients treated with prucalopride (range: 20 -27 % ) than among those who received placebo (range: 8 -12 % ) ( 9 -11 ) . Th e proportion of responders is also higher in the prucalopride than in the placebo group in the present study (42 % for prucalopride 2 mg and 21 % for placebo) but, interestingly, is almost twice as high for both placebo and prucalopride groups than in the phase 3 trials. Patients included in the present study were demographically representative of the whole population included in the phase 2 trials in which they took part, which also had a higher proportion of responders than the phase 3 trials. Th is suggests that the diff erences in response rate between the present study and the phase 3 trials are not due to selection of a responsive patient population for the current analysis, but may be explained by other diff erences between the patients or methodologies included in the phase 2 and phase 3 trials.
Chronic constipation is a largely symptomatic disorder, with the exact symptoms varying extensively among patients. Th e Rome III criteria provide the most widely used defi nition of chronic constipation, but in clinical practice patients do not always meet these criteria. Th is may partly be due to the diff erent etiologies of the condition (e.g., slow transit) and it has been suggested that diff erences in the types of symptoms and symptom severity could be good indicators of the underlying pathophysiology ( 26 ) .
Despite perceived associations between CTT and the symptoms of constipation, there has been little direct evidence of this relationship to date ( 2 ) . In a comparison of women with and without functional bowel disorders, Bharucha et al. ( 27 ) identifi ed a relationship between stool consistency and symptom severity. For example, hard stools were associated with increased straining, and straining was experienced more frequently by patients with constipation than by participants without constipation. Increased CTT in healthy patients has been demonstrated to result in harder stools than when CTT is in the normal range ( 28 ) , suggesting a link between increased CTT and increased straining. Consistent with this, there was a correlation between increasing CTT and harder stool consistency in the present study.
Th e present study provides the fi rst example of a correlation between idiopathic slow CTT and severity of symptoms. Previous studies have shown that loperamide-induced constipation (which slows colonic transit) in healthy volunteers induces bloating and colonic pain, consistent with the idea that constipation symptoms and slow transit are linked ( 29 ) . In patients with irritable bowel syndrome, a relationship has been suggested between transit time and bloating, but both delayed and accelerated intestinal transit have been associated with this symptom ( 30 ) . In the present study, a slower CTT was linked to harder stools, a greater need to strain, increased frequency of unproductive calls to stool, increased bloating, increased incomplete evacuation and abdominal pain / cramps, as well as with reduced urgency compared with a normal CTT. Th ese results can be explained by the hypothesis that a slow CTT reduces the volume of intestinal contents delivered to the rectum, which results in evacuation diffi culty and associated symptoms.
If this hypothesis was correct, a constipation therapy targeted at reducing CTT might have a direct impact on alleviating symptoms in patients with slow CTT. Recent studies on the eff ect of pelvic fl oor biofeedback as a therapy for chronic constipation have demonstrated improvements in constipation symptoms ( 31 ) . However, despite early studies indicating the effi cacy of this treatment for the majority of patients with chronic constipation ( 32, 33 ) , recent evidence suggests that the technique works preferentially for patients with pelvic fl oor in coordination, with negligible eff ect 
WHAT IS NEW HERE
3 Prucalopride reduces CTT in patients with chronic constipation.
3 Increased CTT is associated with increased severity of constipation symptoms.
in those with slow-transit constipation ( 34 ) . Th is supports the idea that transit and evacuation diffi culty are intimately linked, both in terms of underlying pathophysiology and the resulting symptoms. Th e present study provides evidence that prucalopride reduces CTT and stool hardness, suggesting a mechanism through which this drug reduces the symptoms of constipation. Th e suggested relationship between slow transit and hard stools discussed above ( 28 ) can be explained by increased water reabsorption during the prolonged time in the gut. In the present study, there was a reduction in the proportion of bowel movements with hard / very hard stools following prucalopride treatment, but this was seen only in patients who achieved normal CTT at the end of the trials. Th is suggests that the prucalopride-induced reduction in CTT is the mechanism resulting in stool soft ening. If transit remains slow following treatment, this improvement in stool consistency does not occur.
Limitations
A limitation of the present study is that these pooled results were part of a retrospective analysis using data collected aft er 4 weeks of treatment for two of the trials (INT-1 and USA-3) and aft er 12 weeks for the third trial (INT-2). Second, there are some inconsistencies among the pooled trials: notably, the terminology used to assess symptoms was diff erent across the three trials. Although similar terms were pooled, the diff erences identifi ed in our integrated analysis may relate to variability in symptom defi nition across the trials. However, we feel that the symptom profi les we have used refl ect clinical practice in a way that is recognizable to health-care professionals treating patients with constipation, and that these profi les are therefore clinically relevant.
Conclusions
Th is study is the fi rst to show a clear relationship between increased CTT and the severity of symptoms of constipation, including abdominal cramps, bloating, hard stools, decreased bowel movement frequency, straining, and an increased number of unproductive calls to defecate. Consistent with results from previous studies, patients with slow or very slow CTT at baseline treated with prucalopride were more likely than those receiving placebo to return to normal CTT by the end of the study. Th ese patients had an accelerated CTT during the course of the trials and fewer hard stools, suggesting the effi cacy of the mechanism through which prucalopride leads to improved symptoms in patients with chronic constipation.
